Events
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
-
-
Microbiome provides new clues to determining development of colon cancer
A mutant protein found in humans with colon cancer blocks a pathway that regulates proliferation…
ESMO 2019: DNA profiling may hold key to better treatment options in carcinoma of unknown primary
DNA profiling is revealing novel treatment choices for patients with cancer whose disease has spread…
ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men
A drug used for breast and ovarian cancer is more effective than modern targeted hormone…
First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA breast cancer patients
- New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments
- Irradiating chest lymph nodes in patients with early stage breast cancer improves survival without increasing side effects
- Most Women With Early Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.